Taltz (ixekizumab) recruitment ends on 31st July 2025

Taltz (ixekizumab) recruitment ends on 31st July 2025

Please be aware that BADBIR cannot accept any new registrations at baseline for patients starting Taltz after 31st July. Participants must have started treatment and provided consent before 1st August to be accepted. If participants signed consent and commenced Taltz...

Ustekinumab biosimilars

BADBIR Participants Using the Patient Portal Your data Participant FAQs Patient Newsletters Clinicians Eligibility Study information Conducting BADBIR remotely Associate Principal Investigator Scheme Centre Report Average daily dose Participating centres Steering...